2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2872

Elevated mTORC1 Signature in B Cells from Sjögren’s Syndrome Patients: mTOR Inhibition As a Novel Therapeutic Strategy to Halt B Cell Hyperactivity
Abstract Number: 1254

Eliciting the Research Priorities of Parents and Children with Juvenile Myositis
Abstract Number: 1084

Emdhaq: (electronic multidimensional health assessment questionnaire) to Record and Document eRAPID3 (electronic routine assessment of patient index data3) and eFAST3 (electronic fibromyalgia assessment screening tool3) in Routine Rheumatology Care
Abstract Number: 1978

Employment Status in Fibromyalgia: Comparison of Employed and Unemployed Patients and Predictors of Unemployed Status
Abstract Number: 646

Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Is a Susceptibility Factor for Early Axial Spa Meeting the ASAS Classification Criteria: Results from the Spondyloarthritis Caught Early and DEvenir des Spondyloarthrites Indifférenciées Récentes Cohorts
Abstract Number: 686

Endothelial Dysfunction in Systemic Lupus Erythematosus Patients without Cardiovascular events and Risk Factors: Correlation with Microvascular Alterations and angiogenic t Cells
Abstract Number: 2370

Endothelial Nitric Oxide Synthase Gene Polymorphism As a Risk Factor of Hypertension in Patients with Rheumatoid Arthritis
Abstract Number: 2660

Endothelin-1 and Interleukin-6 Serum Levels Are Associated with More Severe Vasculopathy in Patients  with Systemic Sclerosis
Abstract Number: 489

Endotypic Clustering of Rheumatoid Arthritis Patients through the Use of Tissue Specific Serum Biomarkers Identifies Structural Progressors
Abstract Number: 233

Engaging Community Stakeholders through a National Lupus Education Workshop
Abstract Number: 220

English Language Proficiency and Total Joint Replacement Outcomes: Is There a Relationship?
Abstract Number: 557

Enhanced Expression of NLRP3 Inflammasome-Related Inflammation in Peripheral Blood Mononuclear Cells in Sjögren’s Syndrome
Abstract Number: 85

Enhanced IFN-γ STAT1 Signaling in CD4 T Cell Populations and Attenuated IL-2 STAT5 Signaling Contribute to the Pathogenesis of Rheumatoid Arthritis (RA)
Abstract Number: 1608

Entheseal Involvement in Systemic Lupus Erythematosus: An Ultrasound Study
Abstract Number: 2860

Enthesitis-Related Arthritis: Axial -Pattern Is Associated with an Expansion of Peripheral Th17 Populations .

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].